Glenn Short

Atai Life Sciences' (NASDAQ: ATAI) wholly-owned subsidiary EmpathBio has received Medsafe central regulatory and the Health and Disability Ethics Committees (HDEC) approvals to begin participant enrollment in its Phase 1 trial of proprietary MDMA-based drug EMP-01, designed to ...

ATAI Life Sciences NV (NASDAQ: ATAI) is deploying a multipronged approach to accelerate the development of mental health treatments.  The company operates a decentralized hub and spoke model in which each of ATAI's platform companies focuses on one lead compound in a single...

Compass Pathways Files for an IPO at NASDAQ UK-based Compass Pathways wants to become the first psychedelics company to list on a major U.S. stock exchange. The psilocybin research company intends to make its initial public offering (IPO) through NASDAQ under the ticker symbol...

Psychedelics and biotech company ATAI Life Sciences announced on Monday the launch of a new subsidiary that will focus on the development of MDMA derivatives for the treatment of post-traumatic stress disorder and other indications. EmpathBio will be a wholly owned subsidiary of ATAI, led by CEO...

Psychedelics and biotech company ATAI Life Sciences announced Wednesday the launch of Viridia Life Sciences. This wholly-owned subsidiary will be dedicated to the study and production of the DMT molecule (N,N-Dimethyltryptamine). DMT is a psychoactive alkaloid present in Ayahuasca, a hallucinogenic...